The compelling case for anti-CD3 in type 1 diabetes

Journal article

Open access

Peer reviewed

Diabetes (New York, N.Y.), Vol.62(11), pp.3656-3657

2013-11

PMCID: PMC3806623

PMID: 24158991

Abstract

Female

Male

Antibodies, Monoclonal, Humanized - therapeutic use

C-Peptide - metabolism

Humans

Diabetes Mellitus, Type 1 - drug therapy

url

https://doi.org/10.2337/db13-1157View

Published (Version of record) Open

5 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.26 Diabetes; 1.26.1016 Type 1 Diabetes
Web Of Science research areas: Endocrinology & Metabolism
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: The compelling case for anti-CD3 in type 1 diabetes
Creators: Jay S Skyler - Diabetes Research Institute, University of Miami, Miami, Florida
Publication Details: Diabetes (New York, N.Y.), Vol.62(11), pp.3656-3657
Academic Unit: Miller School of Medicine; Diabetes Research Institute (DRI)
Language: English
Resource Type: Journal article
PMID: 24158991
PMCID: PMC3806623
Record Identifier: 991031599405702976